ResearcherNational Institutes of HealthActive in the last 2 years

William Douglas Figg

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2428-5613; OpenAlex author ID A5079418869; NIH RePORTER profile ID 9979589. Sources: OpenAlex.

Their work

Papers: 3
Trials: 0
Grants: 1
Labs led: 0
Collaborators: 10

Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: 2 papers · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 grant

Papers 3

Grants 1

Using Clinical Pharmacology Principles to Develop New Anticancer Therapies ZICSC006537 ↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Christine Alewine · 2 shared papers, 2016–2020 · strength 0.18
- Paper Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreat… DOI 10.1158/1078-0432.ccr-19-2586 ↗
- Paper Targeting the microenvironment of pancreatic cancer: overcoming treatment barriers and improving local immune responses. DOI 10.1007/s12094-015-1459-8 ↗
Resham Bhattacharya · 1 shared paper, 2020 · strength 0.12
- Paper Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro. DOI 10.2147/ijn.s234112 ↗
Chandra Kumar Elechalawar · 1 shared paper, 2020 · strength 0.12
- Paper Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro. DOI 10.2147/ijn.s234112 ↗
Priyabrata Mukherjee · 1 shared paper, 2020 · strength 0.12
- Paper Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro. DOI 10.2147/ijn.s234112 ↗
Raffit Hassan · 1 shared paper, 2020 · strength 0.10
- Paper Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreat… DOI 10.1158/1078-0432.ccr-19-2586 ↗
Jane B Trepel · 1 shared paper, 2020 · strength 0.10
- Paper Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreat… DOI 10.1158/1078-0432.ccr-19-2586 ↗
Ira Pastan · 1 shared paper, 2020 · strength 0.10
- Paper Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreat… DOI 10.1158/1078-0432.ccr-19-2586 ↗
Zishuo I. Hu · 1 shared paper, 2020 · strength 0.10
- Paper Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreat… DOI 10.1158/1078-0432.ccr-19-2586 ↗
Julius Strauss · 1 shared paper, 2016 · strength 0.08
- Paper Targeting the microenvironment of pancreatic cancer: overcoming treatment barriers and improving local immune responses. DOI 10.1007/s12094-015-1459-8 ↗
Austin G. Duffy · 1 shared paper, 2016 · strength 0.08
- Paper Targeting the microenvironment of pancreatic cancer: overcoming treatment barriers and improving local immune responses. DOI 10.1007/s12094-015-1459-8 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.